These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17588476

  • 1. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
    Olivieri A, Capelli D, Troiani E, Poloni A, Montanari M, Offidani M, Discepoli G, Leoni P.
    Exp Hematol; 2007 Jul; 35(7):1074-82. PubMed ID: 17588476
    [Abstract] [Full Text] [Related]

  • 2. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [Abstract] [Full Text] [Related]

  • 3. Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia.
    Ferrara F, Mele G, Palmieri S, Pedata M, Copia C, Riccardi C, Izzo T, Criscuolo C, Musto P.
    Hematol Oncol; 2009 Dec; 27(4):198-202. PubMed ID: 19475701
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy of IA regimen followed by FLAG regimen in the treatment of acute myeloid leukaemia].
    Qian SX, Li JY, Hong M, Lu H, Wu HX, Qiu HX, Zhang SJ, Chen LJ, Xu W, Sheng RL.
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):22-5. PubMed ID: 19563030
    [Abstract] [Full Text] [Related]

  • 5. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
    Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E.
    Haematologica; 2002 Aug; 87(8):804-7. PubMed ID: 12161355
    [Abstract] [Full Text] [Related]

  • 6. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 7. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
    Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE.
    Cancer; 2002 Aug 01; 95(3):581-7. PubMed ID: 12209751
    [Abstract] [Full Text] [Related]

  • 8. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
    Ferrara F, Palmieri S, Annunziata M, Viola A, Pocali B, Califano C, D'Arco AM, Mele G.
    Bone Marrow Transplant; 2004 Oct 01; 34(7):573-6. PubMed ID: 15258559
    [Abstract] [Full Text] [Related]

  • 9. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan.
    Ferrara F, Palmieri S, Pedata M, Viola A, Izzo T, Criscuolo C, Mele G.
    Hematol Oncol; 2009 Mar 01; 27(1):40-5. PubMed ID: 19206083
    [Abstract] [Full Text] [Related]

  • 10. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Br J Haematol; 2005 Oct 01; 131(2):172-9. PubMed ID: 16197446
    [Abstract] [Full Text] [Related]

  • 11. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E.
    Leuk Res; 2005 Jun 01; 29(6):649-52. PubMed ID: 15863204
    [Abstract] [Full Text] [Related]

  • 12. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS.
    Zhonghua Zhong Liu Za Zhi; 2006 Sep 01; 28(9):706-8. PubMed ID: 17274381
    [Abstract] [Full Text] [Related]

  • 13. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S, Paydas S, Disel U, Sahin B.
    Am J Ther; 2006 Sep 01; 13(5):389-93. PubMed ID: 16988532
    [Abstract] [Full Text] [Related]

  • 14. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
    Pigneux A, Perreau V, Jourdan E, Vey N, Dastugue N, Huguet F, Sotto JJ, Salmi LR, Ifrah N, Reiffers J.
    Haematologica; 2007 Oct 01; 92(10):1327-34. PubMed ID: 18024370
    [Abstract] [Full Text] [Related]

  • 15. Cytoprotection in acute myelogenous leukemia (AML) therapy.
    Grosso D, Filicko J, Garcia-Manero G, Beardell F, Brunner J, Cohn J, Ferbér A, Martinez J, Mookerjee B, Rose L, Tice D, Wagner JL, Capizzi R, Flomenberg N.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):67-73. PubMed ID: 15726527
    [Abstract] [Full Text] [Related]

  • 16. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V, Tzouvara E, Vartholomatos G, Chaidos A, Tsiara S, Bourantas KL.
    J Exp Clin Cancer Res; 2004 Sep 01; 23(3):447-54. PubMed ID: 15595635
    [Abstract] [Full Text] [Related]

  • 17. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, Reiter A, Ritter J, Dworzak M, Stary J, Reinhardt D.
    J Clin Oncol; 2006 Sep 20; 24(27):4499-506. PubMed ID: 16983120
    [Abstract] [Full Text] [Related]

  • 18. Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
    Mele A, Leopardi G, Sparaventi G, Nicolini G, D'Adamo F, Guiducci B, Barulli S, Malerba L, Stramigioli S, Talevi N, Politi P, Isidori A, Malagola M, Piccaluga P, Visani G.
    Eur J Haematol; 2005 Apr 20; 74(4):277-81. PubMed ID: 15777338
    [Abstract] [Full Text] [Related]

  • 19. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.
    Ferrara F, D'Arco AM, De Simone M, Mele G, Califano C, Pocali B, Danise P, Palmieri S.
    Haematologica; 2005 Jun 20; 90(6):776-84. PubMed ID: 15951290
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.
    J Med Assoc Thai; 2009 Sep 20; 92(9):1143-9. PubMed ID: 19772172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.